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ABSTRACT 
The aim of this thesis was to synthesize 1H-benz[d]imidazole- and 
benzo[c][1,2,5]oxadiazole-derived compounds active against intracellular 
bacterium Chlamydia pneumoniae and protozoan parasites Leishmania 
donovani, and Plasmodium falciparum, and to find new potent compounds 
as hit molecules for further development. 
A number of issues dictate the importance of the pursuit of this work. 
First, C. pneumoniae contributes to human health by being a widespread 
bacterium and causing respiratory infections such as pneumonia. In 
addition, atherosclerosis has been shown to be connected to the bacterium’s 
persistent form. Second, a neglected tropical disease, visceral leishmaniasis 
in turn is caused by a protozoan parasite L. donovani and can be fatal if left 
untreated. Its current treatments suffer from toxicity, poor compliance and 
prevalent parasite resistance. Third, another tropical disease, malaria is 
caused by protozoan parasites belonging to the genus Plasmodium. P. 
falciparum resistance to recent antimalarial drugs is an ever growing and 
alarming issue, and there is an unmet medical need for new antimalarial 
chemotypes targeting the different parasite forms present in various stages of 
the Plasmodium life cycle. 
Heterocyclic chemical structures are widely used in the early drug 
discovery process and in compound screening. At the outset of this study, a 
series of 2-arylbenzimidazole derivatives was designed to target C. 
pneumoniae and L. donovani. Further development of these 2-
arylbenzimidazoles resulted in a set of 2-aminobenzimidazoles against P. 
falciparum. Benzoxadiazole derivatives were designed against L. donovani. 
Facile and general synthesis routes for the preparation of both benzimidazole 
and benzoxadiazole derivatives were developed. 
In order to study structure-activity relationships of the antichlamydial 
and antileishmanial 2-arylbenzimidazoles, the left, right and central parts of 
the core molecular structure were modified and different substitution 
patterns were employed. Antichlamydial, antileishmanial and antimalarial 
inhibition activities were related to the different structural modifications 
carried out. Antichlamydial and antileishmanial 2-arylbenzimidazoles or 
benzoxadiazole derivatives inhibited target pathogens at the micromolar 
level. 
Furthermore, 2-aminobenzimidazoles were studied as antimalarial 
compounds. The best derivative from this study inhibits growth of P. 
falciparum (IC50 94 nM) and has a good pharmacokinetic profile. The 
compound turned out to be efficacious in vivo against P. falciparum upon 
once a day oral administration. 
In this study, selectivity of the 2-arylbenzimidazoles against selected 
intracellular parasites over free living (planktonic) pathogens e.g. 
ii 
Escherichia coli was observed. This is a great advantage from the 
antimicrobial drug discovery point of view. In spite of the mechanisms of 
action of the studied derivatives remaining elusive, it was possible to show in 
this study that antimicrobial compound design can be successful even in the 
case of unknown macromolecular targets of C. pneumoniae, L. donovani, 
and P. falciparum. 
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1 GENERAL INTRODUCTION 
Increasing resistance to antibiotic and antiparasitic agents emphasizes the 
need for new antimicrobial and antiparasitic discovery. Antibacterial 
resistance can be addressed by finding new antibacterial targets and/or by 
modifying existing antibacterial agents to overcome specific resistance 
mutations. Antibacterial drug discovery is challenging, as it might be easy in 
some cases to find compounds that kill bacteria, but a compound which is 
worthy of development might prove challenging to find.1 There has been 
discovery void of new antimicrobial substances during recent years. 
Moreover, many antiparasitic drugs have been first discovered to some other 
indication and less novel agents to treat antiparasitic diseases have been 
used.2  
In order to find biologically active antimicrobial and antiprotozoal small 
molecular compounds, high-throughput screening and structure-based 
approaches have been used at early stages of drug discovery.3–5 From 
screening approaches, phenotypic and target-based screening are used 
successfully.6,7 
Structurally and mechanistically new antibiotics are needed, malaria 
control is one of the highest priorities on the international health agenda 
currently9, and leishmaniasis is a pathogen target categorized as a neglected 
disease by The World Health Organization8. Diverse antiparasitic research 
efforts have increased in recent years around a consensus of necessity for 
such work and increased funding from many non-profit foundations. 
Antimalarial work has reached a couple of milestones as malaria mortality 
rates are significantly decreasing and, for example, a malaria vaccine has 
progressed to phase III clinical studies.9,10 There are numerous publications 
of the antimalarial agents, whereas research for novel antichlamydial 
compounds consists of just few publications during recent years. Target 
pathogens Chlamydia pneumoniae, Leishmania donovani, and Plasmodium 
falciparum are briefly introduced in this chapter together with some points 
of challenges in the early drug discovery process of parasitic diseases. 
Heterocycles are widely used and found in biologically active small 
molecules in diverse therapeutic areas.11 Heterocycles are used as a starting 
point of molecules discussed in this thesis. In this literature introduction, 
core structures of the work, 1H-benz[d]imidazoles and 
benzo[c][1,2,5]oxadiazoles (referred to as benzimidazole and benzoxadiazole, 
respectively), are discussed in brief. 
2 
1.1 TARGET PATHOGENS 
1.1.1 Chlamydia pneumoniae 
 
Chlamydia pneumoniae is a widespread intracellular Gram-negative 
bacterium causing approximately 10% of community-acquired pneumonia 
and 5% of bronchitis and sinusitis among the adult population. It has a 
unique life cycle, which consists of a metabolically active intracellular form 
(reticulate body) and an infective extracellular form (elementary body) 
(Figure 1).12 Chlamydia infection can also enter a chronic stage (specific 
intracellular non-replicating form, aberrant body).13,14 The majority of 
studies support the association of increased risk of atherosclerosis with C. 
pneumoniae infection.15–17 C. pneumoniae infection can contribute to 
atherosclerosis by indirect and direct mechanisms. C. pneumoniae infection 
is also associated with other severe diseases and inflammatory processes like 
asthma18–20, chronic obstructive pulmonary disease21, Alzheimer’s disease22–
24 and lung cancer25, although not totally without controversial opinions. 
 
 
Figure 1 C. pneumoniae life cycle. EB elementary body, RB reticulate body, AB aberrant 
body. 
Chlamydial infection is treated with tetracyclines, macrolides, and 
fluoroquinolones, antibiotics which affect protein synthesis and DNA 
replication, using a long treatment time (Figure 2).26,27 In case of persistent 
(chronic) infections, however, this treatment modality can fail .28,29 
 
 
Figure 2 Drugs used to treat C. pneumoniae infection. 
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In general, antibacterial agents can target a broader or more specified group 
of bacteria. Chronic infections and the so-called persister and dormant cells 
also warrant the need for new approaches in the drug discovery process, due 
to the lack of response to most antibiotics, which are primarily effective 
against actively dividing cells.30,31 Chemical diversity is needed in antibiotic 
drug discovery.1,32 Usually, the chemical structures of antibacterial 
compounds differ from the other orally administrated drugs by being more 
hydrophilic and slightly larger in molecular size.32,33 For example, in 
commercially available chemical libraries consisting of compounds fulfilling 
the criteria for drug-likeness, this might lead to a situation where potential 
antibacterial compounds are excluded. In the search for new antibacterial 
compounds, natural product screening is encouraged, because of their vast 
structural and molecular diversity.33,34 
In antichlamydial drug discovery, the bacterium life-cycle causes 
challenges in eradicating the infection.35 The antichlamydial compound has 
to penetrate the host cell plasma membrane, inclusion membrane 
surrounding the bacterium in its replicating form, and finally the outer 
membrane of Gram-negative bacterium in order to be able to affect the 
metabolically active form of the bacterium. Another option is to try to affect 
other cellular components of C. pneumoniae, for example those that do not 
reside inside the reticulate body membrane. 
Virulence factors have been considered as antichlamydial small molecule 
targets. Type 3 secretion system (T3SS) is an essential contributor to 
chlamydial virulence known to be present in C. pneumoniae36, and 
compounds inhibiting Yersinia pseudotuberculosis T3SS have been shown to 
affect also C. pneumoniae growth.37 Also some non-conventional 
antimicrobial agents are studied as antichlamydial compounds. Ca2+ channel 
blockers, such as nifedipine, have been shown to enhance antibiotic 
susceptibility of C. pneumoniae infection, and lipid lowering drug 
(simvastatin) has been shown to have antichlamydial affect by decreasing the 
viable chlamydial count.38,39 Compounds with new mechanisms of action 
might turn out to be a viable solution to improve the current antichlamydial 
treatment. 
1.1.2 Leishmania donovani 
 
Leishmaniasis is a neglected tropical disease caused by intracellular parasites 
belonging to the kinetoplastid genus Leishmania.40 Four different clinical 
forms are specified: visceral, cutaneous, mucocutaneous, and diffuse 
cutaneous leishmaniasis (post kala-azar leishmaniasis). Leishmania is 
transmitted via a bite from the Phlebotomus and Lutzomyia sand flies. 
Leihsmaniasis is a strongly poverty-associated disease and approximately 1.3 
million new cases occur annually, 300 000 of which are visceral 
leishmaniasis.41 A majority of visceral leishmaniasis cases (90%) occur in six 
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countries (Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan).42 
Visceral leishmaniasis caused by L. donovani (in the Indian subcontinent 
and East Africa) or L. infantum (L. chagasi) (in the Mediterrean basin, 
Central, and South America) is fatal within two years if left untreated, 
causing 20-40,000 deaths per annum. Symptoms of the infection occur after 
2-6 months of incubation time. These symptoms include fever, weakness and 
weight loss. The parasite also invades the spleen and liver, causing 
enlargement of these organs.43 
 
 
Figure 3 Amphotericin B and its lipid formulation, miltefosine and paromomycin are studied 
as combination therapies to treat visceral leishmaniasis.
54
 
Current drugs in use are pentavalent antimonials, amphotericin B and its 
lipid formulations, miltefosine, paromomycin, and pentamidine.44 The 
existing treatments suffer from toxicity, parasite resistance and poor patient 
compliance.45–47 Furthermore, drug sensitivities towards different 
Leishmania species vary strongly.48 Coinfection with HIV is known to affect 
drug efficacy,48,49 and the number of cases is increasing alarmingly.50 
Multidrug therapy (Figure 3) is probably a solution to these problems in the 
treatment of visceral leishmaniasis, as several combination therapies studied 
have given promising results.51–54 
Leishmania has a digenetic life cycle.55 Leishmania parasite has two 
morphological forms (Figure 4), a non-motile amastigote form in the 
mammalian host and a motile promastigote in vector. 
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Figure 4 Life cycle of L. donovani. 
Antileishmanial-drug discovery is focused on treatments which present an 
acceptable cost, short duration, and oral administration. In general, 
treatments are sought that are feasible in circumstances where leishmaniasis 
is usually found.2 Four clinical forms and seventeen different species of 
Leishmania are the cause for an urgent need of novel drugs with different 
pharmacokinetic profiles as topical and oral drugs are used for treating 
different forms of leishmaniasis. Visceral leishmaniasis, which is the variant 
that causes mortality, is studied in the most detail.56 Varying sensitivities of 
the strain and species causes challenges in testing antileishmanial drugs, as 
there are regional differences in responses to drugs.57 A lot of research has 
been carried out to find new and potent antileishmanial lead compounds and 
clinical candidates.58,59 
Both promastigote and amastigote forms of Leishmania are used to assay 
antileishmanial compounds. Assays using axenic amastigotes afford a simple 
and rapid approach for screening compounds, but antileishmanial activity 
should be confirmed by using the intracellular amastigote model, because the 
axenic amastigote screens do not necessarily correlate to intracellular 
amastigote model.60,61 An intracellular amastigote model (mouse peritoneal 
macrophages) is recommended as “the golden standard” for antileishmanial 
drug screening, and the intracellular amastigote assay (in macrophages) is 
generally regarded to be a good in vitro model for predicting clinical activity. 
62 Alternatively an ex vivo model using a splenic explant culture system from 
hamsters infected with luciferase-transfected L. donovani can also be used to 
screen antileishmanial compounds.63 
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1.1.3 Plasmodium falciparum 
 
Associated strongly to poverty, malaria still kills approximately 600,000 
people per year, mostly in the African continent.9 Malaria is caused by 
protozoan parasites belonging to the genus Plasmodium. P. falciparum, P. 
vivax, P. malariae, and P. knowlesi are known to infect humans: P. 
falciparum and P. vivax are the main types responsible for mortality. 
Children under the age of five (78% of malaria deaths) and pregnant women 
are under the highest risk. P. falciparum resistance to antimalarial drugs is 
an ever growing issue. Nowadays also artemisinin resistant strains have been 
discovered in addition to chloroquine and pyrimethamine resistant 
strains.64,65 Although artemisinin-based combination therapies (Figure 5) are 
the recommended way of treating plasmodial infections, there is an unmet 
need for novel antimalarial chemotypes. 
 
 
Figure 5 Examples of used compounds in artemisinin-based combination therapies. Used 
combinations are AM+LF, DHA+PYR, AS+AQ, AS+MQ.
66
 
 
Figure 6 P. falciparum life cycle. It consists of stages in human and in vector. 
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There are numerous transitions and stages in P. falciparum life cycle. (Figure 
6).67 The life cycle begins with the bite of an infected Anopheles mosquito.  
Asymptomatic liver stage, symptomatic asexual blood stage and sexual 
gametocytes constitute the P. falciparum life cycle in the host.  
The characteristics considered to be important in antimalarial drug-
discovery include acceptable costs, short treatment duration, and oral 
administration. New antimalarial compounds should have an effect on drug-
resistant parasites and cover four different malaria-causing species.2,66 More 
specifically, new treatments are needed to address blood stage malaria, block 
parasite transmission, and kill dormant hypnozoites (liver form of P. 
vivax).68 Many promising antimalarial lead compounds and candidates have 
been found through rational antimalarial design and HTS (high throughput 
screening) screening.69 
Although most antimalarial testing is concentrated on the asexual blood 
stage, testing against gametocytes and liver stages can also be done.70–73 
Murine models typically utilize rodent parasite P. berghei, but also P. 
falciparum is used nowadays to confirm compound activity against the 
relevant human parasite.74,75 This model relies on the use of immunodeficient 
mice with human erythrocytes. 
 
1.2 SCREENING APPROACHES AND PROPERTIES OF 
ANTIMICROBIAL AND ANTIPARASITIC HIT 
COMPOUNDS 
Screening approaches 
 
Relevant advantages and disadvantages in cases of antibacterial and 
antiparasitic screening can be focused on the following topics. In the case of 
parasitic disease there might be only a limited number of validated molecular 
targets to use for target-based approaches.4 In target-based screening, the 
macromolecular target of the pathogenic microbe is already known, but 
compounds’ activities need to be confirmed by using various cell-based 
assays. Also, structure-based drug discovery can be less successful due to the 
lack of available macromolecular structures, although a growing number of 
structure-based targets and methods promise a higher success-rate in the 
future.5 
The major advantage of phenotypic screening is its focus on the 
compound’s activity in the whole cell. This means that issues like cell 
penetration, and cell uptake or efflux are captured in the assay, as are all the 
targets and biological pathways that one might want to target.4,76,77 The 
major challenges in phenotypic screening include maintaining biological 
cultures as well as the target identification. However, there are many ways to 
investigate macromolecular pathogen-targets, including: affinity 
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chromatography, expression cloning, and protein microanalysis.78 The 
compounds found by using phenotype screening can target multiple 
microbial macromolecules, but this also means that the chemical 
optimization of antimicrobial activity may not be driven by one target only.3  
 
Properties of the hit and lead compound 
 
The hit compound and, later on, the resulting lead compound, should possess 
some characteristic properties to increase the probability of its procession to 
the next stage of drug discovery, lead optimization. Examples of these 
properties are shown in Table 1. 
 
Table 1. Examples of essential properties of experimental compounds in antimicrobial and 
antiparasitic drug discovery at the hit/lead phase. Collected examples deal with 
antimalarial, antiparasitic and overall antimicrobial studies.
2,68,79
 
Efficacy 10 nM - 10 µM / parasitic IC50 1 µg/mL 
Cytotoxicity / Selectivity At least ten-fold selectivity over mammalian cell line 
Cyt P450  IC50 > 10 µM 
hERG IC50 >10 µM 
Solubility >200 µM 
Intrinsic clearance <3 mL/min/kg 
HSA binding <95% 
In vitro activity against resistant strains  
Lead in vivo active against parasite ≤100 mg/kg, candidate <10 mg/kg per oral 
Lead not overtly toxic in animals at efficacious dose 
 
Desired properties are listed in a so-called target product profile. Each case is 
considered separately, but efficacy, safety and metabolic stability are very 
important. These also include the potential to interfere with the metabolic 
cytochrome P450 enzymes to predict potential drug-drug interactions, 
human-serum-albumin binding, which reflects on the free fractions of the 
drug and has implication for drug function in vivo,80 and finally hERG (the 
human ether-à-go-go-related gene), which is associated to possible 
cardiotoxicity, a major concern of drug safety81–83. Blockage of hERG K+ 
channels causes abnormality of cardiac muscle repolarization, which results 
in prolongation of the QT interval. hERG cardiotoxicity has resulted in 
several withdrawals of drugs from the market. 
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1.3 HETEROCYCLIC CORE STRUCTURES 
1.3.1 Benzimidazole 
 
 
Figure 7 Benzimidazole structure with its tautomer. 
Benzimidazole structure is given in Figure 7. Benzimidazole derivatives have 
shown a wide variety of biological activities.84,85 Antihypertensive, anti-
inflammatory, antimicrobial, antiviral, anthelmintic, antioxidant, and 
antitumor benzimidazole-based compounds are known. In addition, the 
benzimidazole core is present in some psychoactive agents, lipid modulators, 
anticoagulants, and antidiabetic agents. The benzimidazole-derived 
compounds, more relevant for this study, have been reported to possess 
antibacterial,86–90 general antiprotozoal,91–93 antimalarial94–102 and 
antileishmanial activities103–105. Some structurally interesting examples of 
benzimidazole-based compounds are shown in Figure 8. Benzimidazole-
containing drugs are also currently in use (Figure 9), and the benzimidazole 
structure can be found in nature, as a subunit of the complex structure of 
vitamin B12. This diversity of pharmacological activities suggests the 
benzimidazole ring as a privileged structure in medicinal chemistry.106,107 The 
term describes an inherent tendency of certain molecular scaffolds to display 
biological activity. Usually these scaffolds with versatile biological activities 
and binding properties to various macromolecular targets are small ring 
systems. 
 
 
Figure 8 Structurally interesting benzimidazole-derived leads and their selected properties. 
Hedgehog signaling pathway inhibitor
108
 and antimalarial compound
109
 as 
representative examples. 
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Figure 9 Examples of benzimidazole-derived drugs currently in use. Calculated logP 
values.
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Since benzimidazoles have been studied during the past years intensively, 
many related synthesis procedures have also been reported. Examples of 
representative synthesis methods of benzimidazoles are described in Scheme 
1. Generally benzimidazoles have been synthesized via a cyclocondensation 
reaction by treating 1,2-diaminobenzene starting material with carboxylic 
acids under harsh dehydrating reaction conditions, such as HCl111,112 or 
polyphosphoric acid (PPA)114. Nowadays these methods can also be used 
under microwave-assisted reaction conditions.115,116 
 
 
Scheme 1 Representative examples of methods (A116, B117, C115, D118, E119 and F
120
) for facile 
synthesis of the benzimidazole moiety. 
Benzimidazoles can also be synthesized from ortho-aminobenzamides.119,121–
123 Acidic reaction conditions are used in the ring closure step. Another 
widely used method for benzimidazole formation is the condensation of 1,2-
diaminobenzene and an appropriate aldehyde, followed by oxidation. This 
method has been carried out as a one-pot procedure or through isolating the 
intermediate Schiff base. A great number of reagents can be used, for 
example Na2S2O5104,117,124,125, FeCl2126, 1,4-benzoquinone104, Me2S+BrBr-127, 
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H2O2/ceric ammonium nitrate128, DowexTM129, Oxone®130, nitrobenzene131,132, 
Pd(OAc)4133, H2O2/HCl134, benzofuroxan135, Ba(MnO4)2136, DDQ137, Darco® 
KB138, CuSO4139, TMSCl140 and even air without other reaction promoting 
agents141. 
Carboxylic acid derivatives such as nitriles142,143, orthoesters144, esters145, 
and lactones146 can be used as a starting material. An alternative method is to 
use 2-nitroaniline as a starting material.116,125,147 2-Aminobenzimidazoles can 
be synthesized, for example, by using BrCN112,120,148 or isothiocyanate149 as a 
starting material. 
Palladium(0)-catalyzed reactions are used in benzimidazole synthesis. For 
example, (o-bromophenyl)amidine118 or diamines and aromatic halides150 
can be used as starting materials. 
1.3.2 Benzo[c][1,2,5]oxadiazole 
 
 
Figure 10 Benzo[c][1,2,5]oxadiazole structure. 
The structure of benzo[c][1,2,5]oxadiazole (2,1,3-benzoxadiazole), known 
also as benzofurazan, is given in Figure 10. Benzoxadiazoles show a wide 
variety of biological activities and they have been studied against tumors, 
pathogenic bacteria, and parasites as well as in the treatment of neuronal 
disorders.151,152 More relevant to this study, antiparasitic153,154, 
antibacterial155–157 and antimalarial158 activities have been found from 
benzoxadiazoles and their N-oxides. The benzoxadiazole structure is not 
widely used in the current drugs, an example is shown in Figure 11. 
 
 
Figure 11 Benzoxadiazole-derived drug currently in use. Calculated clogP value.
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Benzoxadiazoles are synthesized through benzoxadiazole N-oxides 
(benzofuroxans) mainly in two ways. The first option is a synthesis through 
the azide intermediate. Cyclocondensation of an azide in boiling toluene or 
acetic acid gives the intermediate benzoxadiazole oxide.156,159–161 Another 
method is to use 2-nitroaniline as a starting material and alkaline 
hypochlorite oxidation (KOH in ethanol and sodium hypochlorite).160,162–164 
The subsequent reductive cleavage of the N-oxide is carried out, for example 
12 
by using Ph3P to produce the corresponding benzoxadiazoles. In Scheme 2, 
representative examples of benzoxadiazole syntheses are given. 
 
 
Scheme 2 Examples of methods (A
165
 and B
164
) to synthesize benzo[c][1,2,5]oxadiazoles. 
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2 AIMS OF THE STUDY 
The objective of the current study was to synthesize various heterocyclic, 
mainly benzimidazole- and benzo[c][1,2,5]oxadiazole-derived compounds 
against intracellular pathogens, Chlamydia pneumoniae, Leishmania 
donovani, and Plasmodium falciparum, the causative microbes of such 
diseases as lung chlamydia, leishmaniasis, and malaria, respectively. 
Molecules found by virtual screening166 were used as starting points for the 
design of  antichlamydial, antileishmanial, and antimalarial compounds. The 
library of derivatives was designed to cover enough molecular varieties to 
study relationships between their chemical structures and antimicrobial 
activities. General synthesis routes were developed for each molecular 
scaffold. The ultimate aim was to identify, find, and characterize compounds 
with micro- or nanomolar antimicrobial activities. In addition, the most 
promising compounds were expected to have acceptable properties from the 
medicinal chemistry point of view, to enable continuing with the compound 
optimization and further development. 
 
The more specific aims of the research were 
 
 To design and synthesize 2-arylbenzimidazole derivatives against 
Chlamydia pneumoniae or Leishmania donovani, and study their 
structure-activity relationships (I, II) 
 
 To design and synthesize 2-aminobenzimidazoles as antimalarial 
compounds, study their structure-activity relationships and find a 
developable lead molecule (III) 
 
 To design and synthesize benzoxadiazoles as antileishmanial 
compounds and study their structure-activity relationships (IV) 
 
 
 
14 
3 EXPERIMENTAL 
A detailed presentation of the materials, synthetic, and analytical methods 
can be found in the original Publications I-IV and in the associated 
supporting information. 
The supporting information for original publications I-IV is not included 
in this thesis book. This material is available from the author or via Internet. 
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4 RESULTS AND DISCUSSION 
The main findings of the original publications are described in this chapter, 
with some additional unpublished data. More detailed results can be found in 
the original Publications I-IV. Reaction conditions have not been 
systematically optimized for any of the synthesis routes described, as the 
main objective of the synthetic chemistry part was to produce derivatives for 
various biological tests and antimicrobial assays. 
4.1 DESIGN OF THE DERIVATIVES AND GENERAL 
SYNTHESIS PROCEDURES 
2-Arylbenzimidazoles as antichlamydial and antileishmanial agents 
(Publications I and II) 
 
Design of the 2-arylbenzimidazoles is based on the previous finding of our 
research group that certain 2-arylbenzimidazoles possess micromolar activity 
against Chlamydia pneumoniae.166 Due to the lack of protein structures of C. 
pneumoniae, a related homology model was used. C. pneumoniae 
dimethyladenosine transferase has high active site homology with Bacillus 
subtilis RNA methyltransferase. They are also known to bind their ligands 
similarly.167 Dimethyladenosine transferase is known to be related to 
functions of ribosomal structure. By using a homology model of C. 
pneumoniae dimethyladenosine transferase, a total of 3×105 molecules were 
screened virtually.166 This study revealed the activities of 2-
arylbenzimidazoles and benzo[c][1,2,5]oxadiazoles against C. pneumoniae, 
when selected compounds were tested in vitro. 
Of the selected 2-arylbenzimidazoles, phenyl and 2-thiophene derivatives 
showed antichlamydial activity, and the para-substituted phenyl derivatives 
were inactive (Figure 12).166 As small modifications of the molecular 
structure may change antichlamydial activity dramatically, design of the first 
generation antichlamydial 2-arylbenzimidazoles was focused on small 
variations, and the basic 2-arylbenzimidazole core structure was kept intact. 
 
 
Figure 12 Active and inactive benzimidazole derivatives against C. pneumoniae, found using 
virtual screening.
166
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The same set of 2-arylbenzimidazole derivatives was also tested against L. 
donovani, because structurally similar benzoxazoles, i.e. N-(2-benzoxazole-
2-ylphenyl)benzamides have been shown previously to possess 
antileishmanial activity.168 Extension of the benzimidazole set was planned to 
cover more modifications of the various parts of the molecular scaffold for 
the structure-activity relationship (SAR) study. First and second generation 
modifications of the core structure were the following: substitution of the A- 
and C-rings, alkylation of the B-ring, modification and position of the amide 
linker and variation of the linker, modification and substitution of the D-ring 
(Figure 13). 
 
 
Figure 13 Modification sites of the 2-arylbenzimidazoles as antichlamydial and antileishmanial 
compounds. 
The 2-arylbenzimidazole core structure was synthesized in two steps 
(Scheme 3). First, 1,2-diaminobenzene 6 was diacylated with the 
corresponding benzoyl chlorides in the presence of 4-
(dimethylamino)pyridine (DMAP) in pyridine to produce the bisamides 7 
under MW irradiation. The subsequent cyclization of the bisamides was 
accomplished with p-toluenesulfonic acid (p-TSA) refluxing in p-xylene121 to 
yield 2-arylbenzimidazoles 8 in good yield, except in the case of C-ring-
substituted derivatives (R3≠H), which were obtained in lower yields. Direct 
oxidation methods117,128,130 to synthesize m-nitro-2-arylbenzimidazole were 
tested, but those failed or gave poor yields probably due to the presence of an 
deactivating m-nitro moiety. Thus, the original two-step synthesis route was 
found to be convenient and better yielding. The nitro group of nitroaryl 
benzimidazole was hydrogenated in the presence of palladium(0) catalyst or, 
alternatively, reduction of the A-ring halogenated intermediates (R1= Cl, Br) 
was carried out with SnCl2∙2H2O. Finally, the N-acylated products 10 were 
formed from the corresponding acyl chlorides in the presence of 
triethylamine (TEA) in tetrahydrofuran (THF). 
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Scheme 3 General synthesis route for 2-arylbenzimidazoles. 
Benzimidazole derivatives as antimalarial agents (Publication III) 
 
Our interest in benzimidazole derivatives as antimalarial compounds was 
raised by the recent finding that certain benzimidazole-structured derivatives 
displayed promising antimalarial activity (Figure 14).169 These compounds 
were reported by GSK’s Tres Cantos unit, and with these (and other) 
scaffolds they invited the scientific community to embark on antimalarial 
discovery and to continue developing these scaffolds further. 
 
 
Figure 14 Benzimidazole-derived scaffolds with antimalarial activity.
169
  
2-Arylbenzimidazoles with antichlamydial and antileishmanial propertiesI,II 
were tested against P. falciparum (unpublished results, 66 compounds).170 
The derivative 11 showed the best antimalarial activity, and the initial 
modification was started from this derivative (Figure 15). The first line 
modification was to replace the C-ring with a non-aromatic ring or chain to 
decrease the compound’s lipophilicity. This modification plan was supported 
by the set of antimalarial compounds from TCAMS (Tres Cantos Antimalarial 
Set). The second line modification plan focused on the substitution (or other 
modifications) of the rings A/B and D. 
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Figure 15 Medicinal chemistry plans to modify the original 2-arylbenzimidazole scaffold 
(compound 11). 
The D-ring modified derivatives were synthesized by using a two-step 
synthetic route starting from 2-chlorobenzimidazole 13 (Scheme 4). A 1.5-
day heating of a mixture of 2-chlorobenzimidazole and 1,3-diaminopropane 
gave N1-(1H-benzimidazol-2-yl)propane-1,3-diamine 15. It was then coupled 
to the corresponding benzoic acids to yield the derivatives 16. 
 
 
Scheme 4 General synthesis procedures for the D-ring modified 2-aminobenzimidazole 
derivatives. 
The A-ring modification can be carried out by using a four-step synthetic 
route with formation of the benzimidazole core, starting with the standard  
amidation of 3,5-dichlorobenzoyl chloride 17 (Scheme 5). The subsequent 
reactions of the -aminopropionamide 19 with 1,1'-thiocarbonyldiimidazole 
(TCDI) yielded the corresponding isothiocyanate 20, which on treating with 
a substituted o-diaminobenzene in the presence of N,N′-
dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) gave the desired benzimidazole 
derivatives 22. 
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Scheme 5 The general synthesis procedures for the A-ring modified 2-aminobenzimidazole 
derivatives. 
Benzo[c][1,2,5]oxadiazoles as antileishmanial agents (Publication IV) 
 
Certain benzoxadiazole derivatives have been found to have activity against 
Chlamydia penumoniae166 (Figure 16) in a previous study by our group. We 
expected to also find antileishmanial activity among the benzoxadiazoles, 
because, in our former studies, benzimidazoles had revealed both 
antichlamydial and antileishmanial activities.I, II A set of benzoxadiazoles was 
designed, and the synthetic modifications were directed to substitution of the 
right-hand side phenyl ring, replacement of benzoxadiazole moiety with 
other heterocycles, and modification/simplification of the chain structure 
(Figure 16). 
 
 
Figure 16 Two benzoxadiazole derivatives having antichlamydial activity,
166
 as a basis for the 
design of new derivatives. Figure presents a simplified general structure for the 
benzoxadiazole derivatives and related compounds designed as antileishmanial 
agents. 
Synthesis of benzo[c][1,2,5]oxadiazoles derivatives started from the 
commercially available 4-amino-3-nitrobenzoic acid 25 (Scheme 6). It was 
converted to benzo[c][1,2,5]oxadiazole-5-carboxylic acid 26 by using a two-
step procedure via the N-oxide intermediate that was produced in the 
presence of sodium hypochlorite in an alkaline EtOH-H2O solution. The 
subsequent reduction with P(OEt)3 gave the benzoxadiazolecarboxylic acid.171 
Next, the carboxylic acid was converted to the primary amide 28 via reaction 
of the corresponding acyl chloride 27 with aqueous ammonia. The reaction of 
the obtained primary amide with trifluoroacetic anhydride and TEA in 
THF172 gave the corresponding nitrile 29, which was converted to the 
amidoxime by using hydroxylamine hydrochloride 30 in the presence of TEA 
in EtOH.173 The final step to obtain the N'-[(phenylcarbamoyl)oxy]-
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benzo[c][1,2,5]oxadiazole-5-carboximidamides 31 was carried out in the 
presence of the substituted phenyl isocyanates in THF or CHCl3. 
 
 
Scheme 6 A general synthesis route to the benzo[c][1,2,5]oxadiazole derivatives. 
4.2 BIOLOGICAL ACTIVITY AND STRUCTURE-ACTIVITY 
RELATIONSHIPS 
4.2.1 2-Arylbenzimidazoles as antichlamydial compounds (Publication 
I) 
 
The inhibitory effect of 2-arylbenzimidazoles against C. pneumoniae was 
evaluated in Publication I. Compounds were assayed for C. pneumoniae 
(strain CWL-029) at a concentration of 10 μM using TR-FIA (time-resolved 
fluorometric immunoassay) method174 and for label binding properties as 
well as autofluorescence to exclude false positive signals. The effect of all 2-
arylbenzimidazoles on host-cell (HL, human line175) viability was studied 
after 72 h of incubation with a 10 μM concentration. 
 
 
Figure 17 SAR of 2-arylbenzimidazoles as antichlamydial compounds. Order of the 
substituent and structural parts in figure are based on C. pneumoniae % inhibition 
values (TR-FIA). 
From this set of 2-arylbenzimidazoles (33 compounds), 14 derivatives 
showed at least 80% inhibition activity at a concentration of 10 µM. The SAR 
is reviewed in Figure 17. SAR studies showed that benzimidazole structure is 
essential to activity, and the nature of the D-ring and its substitution is 
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affecting antichlamydial activity. Methylation of the benzimidazole, 
sulfonamide  replacement of the amide linker, and moving of the amide 
connecting structure to the para position instead of meta resulted in 
completely inactive compounds. 
Host cell (HL) viability was over 80% to the majority of the tested  
compounds (exceptions 34, 38, 39), which indicates that 2-
arylbenzimdazole structure is not primarily associated with host cell toxicity 
in vitro. 
From the set of benzimidazoles, nine of the most promising compounds 
(Figure 18) were selected, and antichlamydial activity was evaluated using a 
traditional immunofluorescence labeling (IF) method. Figure 19 presents the 
IF results, including host-cell viability of the selected compounds. 
 
 
Figure 18 The nine potent compounds selected for further testing as antichlamydial agents. 
Compound 33 and 34 inhibited growth of C. pneumoniae, also at low 
concentrations, but derivative 34 had an effect on viability of the HL cells at 
higher concentrations. Interestingly, there was a clear trend that increasing 
concentration of compounds resulted in smaller but still detectable 
chlamydial inclusions. TF-FIA method measures the overall amount of C. 
pneumoniae, whereas IF method measures the number of chlamydial 
inclusions. This explains that, overall, IF inhibition results were partly lower 
than TR-FIA. Only few  of the compounds were able to inhibit C. pneumoniae 
completely. 
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Figure 19 Chlamydial growth inhibition (%) and host cell viability in different concentrations of 
the nine selected compounds. Compounds are divided into the structural group A 
(thiophene derivatives), B (D-ring modified, phenyl or cyclohexane derivatives), and 
C (A-ring substituted). 
The nine selected potent compounds were also tested using the CV-6 strain 
in an acute in vitro infection model (Table 2). These results verify 
antichlamydial activity. The CV-6 strain is a cardiovascular strain, which is a 
human coronary artery-derived clinical isolate known to cause chronic 
infections.176 Overall, results were in line with the result using strain CWL-
29, except compounds 2, 32, and 38 did not inhibit chlamydial growth (MIC, 
minimum inhibition concentration, 196 µM). The detected minimum 
chlamydiocidal concentration (MCC) revealed a range from 3.2 to >196 µM. 
Derivative 33 had the lowest MCC. Growth was also prevented in the 
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subcultures in antibiotic-free medium using the lowest concentration, 
indicating the effect to be chlamydiocidal. 
 
Table 2. MIC and MCC of the selected derivatives using C. pneumoniae strain CV-6. 
 
µM 
Compound MIC MCC 
2 196 >196 
32 >196 >196 
33 3.2-6.3 3.2-6.3 
34 3.2 50.4 
35 6.1-48.9 24.5 
36 24.5 24.5 
37 12.6 12.6 
38 196 >196 
39 12.6 12.6 
Erythromycin 0.17 0.17 
 
The best compound 33 in this study has a minimal inhibitory concentration 
of 10 µM against CWL-029, and 6.3 µM against CV-6. The mechanism of 
action of these compounds is unknown and remains elusive. As derivatives 
affect the growth of C. pneumoniae and they do not show cytotoxicity, it is 
very likely that they are able to cross the host cell membrane. 
 
The importance of conformational effects on the structure–activity 
relationship of these 2-arylbenzimidazoles was studied.177 Minimized energy 
and energy differences were calculated using simplified N-phenylbenzamides 
to describe actual derivatives. It was found that there is a correlation between 
antichlamydial inhibition activity and energy of the D-ring to adopt a 45 
degree angle compared to the C-ring (Figure 20). Compounds which could 
more easily adopt a non-coplanar conformation show higher bioactivity. This 
might indicate that preferred binding conformation to the target is non-
coplanar. 
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Figure 20 Calculated energy difference between the global minimum energy conformation and 
the conformation wherein the C-ring dihedral is forced to an angle of 45 degrees 
(∆E45). Also presented in the table is antichlamydial activity at 10 µM (TR-FIA) for 
the same analogs. At right is an overlay of the conformations of 2-methyl and 2-
(trifluoromethyl)phenyl analogs.
177
 
4.2.2 2-Arylbenzimidazoles as antileishmanial compounds 
(Publication II) 
 
Antileishmanial activity of the 2-arylbenzimidazole derivatives (56 
derivatives, including compounds tested against C. pneumoniae in 
Publication I and extension of the set) was evaluated in Publication II. The 
antileishmanial activity was detected by using a fluorescent viability 
microplate assay with L. donovani (MHOM/SD/1962/1S-Cl2d) axenic 
amastigotes and alamarBlue61 using three concentrations (50, 15, 5 µM) of 
the compounds. 
 
 
Figure 21 Antileishmanial SAR based on the axenic amastigote assay. Order of the 
substituent and structural parts in the figure is based on L. donovani inhibition %. 
Parent 
compound 
Structure of the D-ring ∆E45 
(kcal/mol) 
Chlamydial 
inhibition at 
10 µM 
35 2-methylphenyl  0.0 99 
- 2-(trifluoromethyl)phenyl 0.0 96 
1 phenyl 0.6 99 
32 3-thiophenyl  1.2 68 
2 2-thiophenyl  1.4 89 
- 3-furanyl 1.5 78 
- N-methylpyrrol-2-yl 1.7 80 
- 2-fluorophenyl 2.0 0 
- 2-methoxyphenyl 2.1 0 
- 2-furanyl 3.5 45 
- 1,3-thiazol-4-yl 4.3 39 
- pyridin-2-yl 4.4 36 
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The SAR based on L. donovani axenic amastigote results are summarized in 
Figure 21. Modifications were studied starting from the right-hand side of the 
molecule. Different aromatic, heteroaromatic, non-aromatic rings, and alkyl 
moieties are tolerated in the place of D-ring. Urea and the original amide 
structures constitute the best options for the linker modifications. The 
position of the linker can be meta or ortho. Modification of 2-
arylbenzimidazole was studied using the 2-thiophene moiety as the D-ring of 
the molecule. The A-ring substitution is tolerated as well as alkylation of the 
benzimidazole NH. Finally, substitution of the D-phenyl ring was also 
studied. Many substitution patterns are tolerated, but in this set of new 
derivatives, significantly more active derivatives were not found. 
The importance of the right-hand-side part of the molecule for the activity 
was observed in the case of structurally related N-(2-benzoxazol-2-ylphenyl) 
benzamides.168 A substitution of the pyridine ring was significantly affecting 
antileishmanial activity, when the compounds were assayed against axenic 
amastigotes. 
 
 
Figure 22 Ten benzimidazole derivatives selected for further antileishmanial testing. 
Ten derivatives (Figure 22), which showed over 30% inhibition of axenic 
amastigotes at a concentration of 5 µM, were selected for further evaluation. 
To confirm actual activity of the compounds on infected macrophages they 
were evaluated using THP-1 (a human leukemia monocyte cell line) cells. 
First, cytotoxicity of these derivatives was determined at a concentration of 
15 µM (Table 3). Second, for the seven non-cytotoxic derivatives the 
percentage inhibition in L. donovani-infected THP-1 cells was measured. L. 
donovani axenic amastigote results of the selected derivatives did not vary 
significantly but antileishmanial inhibition values of these derivatives varied 
when they were assayed by using infected THP-1 cells. Interestingly, the 
position of the methylation seems to affect antileishmanial activity 
significantly (compounds 41 and 42, Table 3). To further characterize the 
most active benzimidazole derivatives, their IC50 values on axenic 
amastigotes and fibroblasts (cytotoxicity, murine cell line) were determined. 
Overall IC50 values on axenic amastigotes were lower than expected based on 
initial screening at 5 µM, and this has impact on selectivity index. The 
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cytotoxicity of benzimidazole derivatives in fibroblasts varied between 15 µM 
and 300 µM, indicating that this set of compounds also includes cytotoxic 
compounds. This is why, cytotoxicity liabilities must be considered in the 
future studies. The best compound of the study (42) inhibited L. donovani-
infected THP-1 cells ~ 50% at 5 µM, without signs of cytotoxicity against the 
THP-1 cell line (at concentration of 15 µM) or murine fibroblasts cell line. 
 
Table 3. Cytotoxicity on THP-1 macrophages and NIH/3T3 fibroblasts, and percent inhibition 
of amastigotes in L. donovani-infected macrophages, IC50 on axenic amastigotes, 
and selectivity indices for selected benzimidazole-derived compounds. 
 THP-1 cells  IC50 (µM)  
Cmpd 
Cytotoxicity 15 µM 
± s.e. 
% Inhibition on 
L.donovani infected cells 
5 µM ± s.e. 
 
Cytotoxicity in 
NIH/3T3 fibroblasts 
Inhibition of 
axenic 
amastigotes 
SI 
40 -0.6 ± 4.2 21.7 ± 4.9  15 25.1 0.60 
41 14.1 ± 2.2 4.1 ± 1.4  16.7 10.5 1.59 
42 5.3 ± 4.3 46.4 ± 3.5  >300 17.8 >16.8 
43 -12.9 ± 3.6 27.7 ± 2.4  61.3 22.1 2.77 
44 23.8 ± 0.6 19.8 ± 2.8  22.2 8.8 2.52 
45 54.1 ± 4.5      
46 88.7 ± 1.5      
47 -11.9 ± 2.6 16.0 ± 5.3  15.4 23.4 0.66 
48 62.8 ± 6.4      
49 -4.4 ± 4.9 22.2 ± 1.2  42.2 7.6 5.55 
Amphotericin B  96.7 ± 0.7
a
     
 
 
Structurally related benzoxazoles, which provided the original inspiration to 
test these 2-arylbenzimidazoles as possible antileishmanial compounds, have 
unsatisfactory results in the mouse peritoneal macrophage assay, probably 
due to their poor cell penetration.168 In the case of our 2-arylbenzimidazole 
derivatives, their mechanisms of action are not yet known, but these 
compounds are possibly able to penetrate cell membranes as they retain their 
antileishmanial activity on THP-1 cells. Two-fold increase in their inhibition 
values would benefit, and advance greatly, further study of these compounds. 
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4.2.3 SAR differences of the 2-arylbenzimidazoles as antichlamydial, 
antileishmanial and antimalarial agents (Publications I―III and 
unpublished results) 
 
Synthesized 2-arylbenzimidazole-derived compounds were evaluated as 
antichlamydial, antileishmanial, or antimalarial compounds.I,II,170,177,178 Partly 
the same set of derivatives was tested against three intracellular parasites, C. 
pneumoniae, L. donovani and P. falciparum. Antichlamydial testing was 
carried out with the extension set of antileishmanial benzimidazole 
derivatives in addition to the Publication I compounds. Finally, antimalarial 
testing was carried out with the nearly whole set of benzimidazole-derived 
compounds.  
Differences in their SAR are described in Table 4. The main differences 
are the preferred position of the amide linker and substitutions of the D-ring. 
In addition, alkylation of the benzimidazole NH is allowed in antileishmanial 
compounds. The phenyl ring of the benzimidazole (A-ring) was essential for 
all activities studied. 
Antimalarial testing was carried out at low concentration, and most of the 
tested compounds were inactive. Testing at higher concentrations would 
have probably given more differences in the inhibition activities of the 
compounds as well as more variable SAR data. 
In case of the D-ring, antichlamydial activity was related to the non-
planar orientation of the D-ring, whereas antileishmanial activity seems to be 
more related to the electronic nature of that moiety.I,II,177 In cases of 
antimalarial compounds, 3,5-disubstitution of the D-ring clearly increased 
the antiplasmodial activity of the compounds. 
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Table 4. SAR comparison of 2-arylbenzimidazoles as antileishmanial, antichlamydial and 
antimalarial compounds. These results are based on TR-FIA and unpublished IF 
results (C. pneumoniae)
I,177,178
, a fluorescent viability microplate assay with axenic 
amastigotes (L. donovani)
II
, and whole cell assay at 2 µM (P. falciparum, 
unpublished results)
170
. The table only describes relative activity change between 
derivatives against specific pathogens. The precise amount of activity changes 
cannot be compared between different pathogens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Efficacy of 2-arylbenzimidazoles against other pathogens 
(Publications I, II and unpublished results) 
 
Some 2-arylbenzimidazoles have shown inhibition activity against 
intracellular Gram-negative pathogen C. pneumoniae as well as protozoan 
parasites L. donovani and P. falciparum. A set of benzimidazoles 
(Publication I and selected compounds in II) were also tested against other 
bacteria or fungi. Tested benzimidazoles showed no activity against Gram-
 
 Activity change* 
Sites and modifications C. pneumoniae L. donovani P. falciparum 
1 Replacement with carbon - -  - - 
2 Amide structure with aryl D-ring at 
ortho position 
+ + + - - - 
3 Replacement of amide structure with 
urea 
+ + - - 
4 Replacement of D-ring group with 
various heterocycles 
-  - - / n.e. - 
4 Replacement of D-ring with alkyl - - - n.e. - - 
4 Substitution at para position - -  + - - 
5 3,5-Disubstitution of the D-ring ++ + + + + + 
6 Ortho substitution --  n.e. +/- - 
7 N-alkylation -  - - - - - 
8 Amide structure with aryl D-ring at para 
position 
- - - + - - 
9 N-alkylation - - - n.e. - - - 
9 Replacement with oxygen - - - - - - 
10 Removal of aryl A-ring - - - - - - - - - 
*+++ major increase, ++ moderate increase, + minor increase, n.e. no effect/irrelevant,  - minor decrease, --moderate decrease,  
- - - major decrease 
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negative bacterium Escherichia coli (at a concentration of 50 µM), Gram-
positive bacteria Staphylococcus aureus (50 µM) (except 34, which showed 
also cytotoxicity)I, nor fungus Candida albicans (50 µM)II. A small set of the 
2-arylbenzimidazole derivatives has also been tested against the tuberculosis 
causing Mycobacterium tuberculosis to demonstrate no apparent inhibition 
activity (unpublished data).179 Similarly, no inhibition activity was revealed 
when testing a small set of compounds against non-pathogenic 
Mycobacterium smegmatis and Corynebacterium glutamicum.179 
Selectivity is essential and important, especially critical in the case of 
benzimidazole-derived compounds, because the benzimidazole core has been 
used as a chemical scaffold to target many biological functions, and some 
benzimidazole-structured derivatives might have protein-assay interfering 
properties.180 Our 2-arylbenzimidazoles have shown activity in whole cell-
based assays and selectivity over free living bacteria. 
4.2.5 2-Aminobenzimidazoles as antimalarial compounds (Publication 
III) 
 
2-Aminobenzimidazole derivatives (72 compounds) were evaluated as 
antimalarial compounds in Publication III. IC50 determinations were carried 
out following the standard methods using the 3H-hypoxanthine 
incorporation assay.181 Cytotoxicity was studied by using mammalian HepG2 
cell line182 and hERG inhibition values of all the compounds were tested 
using hERG channel by IonWorks® electrophysiology183–185. The identified 
antimalarial initial hit compound was 3,5-dichlorobenzoyl derivative 11 
(Figure 23). It displayed moderate antimalarial activity against P. 
falciparum, 3D7A in vitro (Table 5). 
 
Figure 23 Selected 2-aminobenzimidazole derivatives.
IV
 
First, the C-ring of the initial hit compound 11 was replaced with various 
non-aromatic rings and functionalized chains. A total of 15 derivatives were 
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synthesized. Replacement of the central aromatic ring with an N-(3-
aminopropyl)amide linker (Figure 23) resulted in a significant increase in 
antimalarial potency (12, Table 5). Compound 12 gave an IC50 of 94 nM, 
lower cytotoxicity, and significantly better solubility than the initial hit 
compound. 
 
Table 5. Selected 2-aminobenzimidazole derivatives and their inhibition activities, hERG 
inhibition, HepG2 toxicity, solubility, and selectivity index (Pf 3D7A IC50 / HepG2 
Tox50). Chloroquine and pyrimethamine were used as antimalarial reference 
compounds.
IV
 
Cmpd 
Pf IC50 
3D7A 
Pf IC50 
W2 
Pf IC50 
V1/S 
hERG 
inhibition 
HepG2 
Tox50 
CLND solubility SI 
 µM  
11 1.52   >14.79 26.3 64 17.3 
12 0.094 0.410 1.029 1.17 36.31 239 386 
50 0.25   22.39 >100 349 >400 
51 2.30   >50.1 >100 322 >43.5 
52 0.90   >50.1 >100 393 >111 
53 0.15   >50.1 25.7 29 171 
Chloroquine 0.036 >1 >1     
Pyrimethamine 0.068 >20 >20     
 
 
The D-ring-modified derivatives (49 compounds) and the A-and B-ring-
modified derivatives (8 compounds) were synthesized. The main structure-
activity relationships of the compounds are summarized in Figure 24. 
Changes in substitution are tolerated in the D-ring  of the benzimidazole 
scaffold, but the derivative 12 remained the most active. Trifluoromethyl-
substituted isonicotinic derivative 50 displayed better cytotoxicity profile 
than the derivative 12. Furthermore, its hERG activity was reduced slightly, 
although its antimalarial efficacy was decreased by over two-fold (Table 5). 
The pyrrolidine derivative 51 serves as another example of this series of 
compounds. It shows neither cytotoxicity nor hERG activity, but its 
antimalarial activity is decreased to an unacceptably low level. Non-aromatic 
derivatives showed moderate potency or loss of potency. The piperidine 
derivative 52 was the most active from this group of compounds, but had 
only moderate antimalarial potency. The A-ring-modified methoxycarbonyl 
derivative 53 showed good antimalarial activity, but suffered from a very 
poor aqueous solubility. The derivative 12 was chosen to undergo a more 
extensive study to verify the potential of this derivative and its chemotype as 
an antimalarial agent. 
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Figure 24 SAR of the 2-aminobenzimidazoles and related derivatives as antimalarial agents. 
Order of the substituent and structural parts in figure are based on P. falciparum 
IC50.
IV
 
When tested against chloroquine resistant and multiresistant strains, W2 
and V1/S, the potency of compound 12 was slightly reduced (Table 5) 
compared to the non-resistant strain. Pharmacokinetic parameters of the 
derivative 12 were determined and they are highly promising for further 
development, as half-life and clearance of 2-aminobenzimidazole derivative 
12 are moderate and its volume of distribution is high (Table 6). 
Furthermore, the compound 12 has good solubility and cell membrane 
permeability. Plasma protein binding is high, but does not prevent 
continuing. 
Parasite reduction rate describes how fast the compound is able to kill 
parasites compared to the known antimalarial drug. Derivative 12 can be 
regarded as a fast/moderate affecting antimalarial compound, like 
dihydroartemisinin and piperaquine. Finally, 2-aminobenzimidazole 12 was 
brought forward for in vivo testing to confirm its in vivo efficacy in the 
humanized mouse model of malaria. 
 
Table 6. Physicochemical and in vitro profile of 12 as well as its pharmacokinetic parameters 
estimated on CD-1 mice (dose iv 1 mg/kg, po 10 mg/kg). 
Profile of compound 12 
Molecular weight 363 Cl (mL/min/kg) 39.7 
clogP 3.4 Vss (L/kg) 6.35 
Solubility FaSSIF (µg/mL) 125 t1/2 (h) iv 1.15 
Artificial membrane permeability nm/s 380 F % 81 
PPB, human 99.6 AUC(0-8) (ng·h/mL) 3447 ± 254 
Ratio blood/plasma 0.72 Cmax (ng/mL) 1663 ± 176 
Parasite reduction rate
186
 Fast/Moderate   
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In vivo efficacy of compound 12 against P. falciparum was studied by using 
mice engrafted with human erythrocytes (Figure 25).74 The compound 12 
was proved to be efficacious in vivo against P. falciparum upon once a day 
oral administration (100 mg/kg). Compound 12 was able to reduce the 
parasitemia under the limit of detection after two doses, showing a parasite 
clearance rate consistent with the known fast-acting antimalarials. The 
microscopic observations suggest that 12 induces in vivo rapid killing of P. 
falciparum erythrocyte stages, because pyknotic parasites emerge two days 
after the initiation of treatment. 
 
 
Figure 25 Efficacy of 12 in the P. falciparum (3D7
0087/N9
) mouse model. Data shows individual 
parasitemia for two mice (M1 and M2) at 100 mg/kg or vehicle. 
IV
 
Further studies are needed to explore the A- and B-ring modification of the 
molecule, and its benzimidazole/guanidine-type moiety for more thorough 
structure-activity relationships, especially those related to the cardiotoxicity-
inducing hERG activity. The hERG activity of some compounds was also 
tested using the Qpatch method in addition of IonWorks® 
electrophysiology.187 Results from these two methods do not correlate 
completely, as only part of the compounds have been tested using both 
methods and thus clear conclusions in this respect cannot be drawn.  In any 
case, non-hERG active compounds containing N-[3-[(benzimidazol-2-
yl)amino]propyl]amide structure were found in both methods, which proves 
that it is possible to find non-hERG active antimalarial compounds from this 
structural group. In addition, increasing the antimalarial potency against 
chloroquine and multiresistant strains of the protozoan parasite P. 
falciparum warrants more studies. 
2-Aminobenzimidazoles have shown antimalarial activity in various 
studies recently. N-Aryl-2-aminobenzimidazoles (Figure 8 in Section 1.3.1) 
have shown nanomolar antimalarial activity and in vivo efficacy, but also 
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lower inhibition activity to resistant strains as well as possible hERG 
issues.109 In another study, analogs structurally related to astemizole were 
investigated as antimalarial agents showing nanomolar activity and good 
selectivity indices.100 Although the chemical structures of these analogs differ 
from those of ours, combined with the fact that 2-aminobenzimidazole is just 
one fragment of compounds tested as antimalarial agents, the found 
similarity is rather interesting and worth keeping in mind. 
4.2.6 Benzo[c][1,2,5]oxadiazoles as antileishmanial compounds 
(Publication IV) 
 
The antileishmanial activity of 25 carboxyimidamide-substituted 
benzoxadiazole and related derivatives was detected by using a fluorescent 
viability microplate assay with L. donovani (MHOM/SD/1962/1S-Cl2d) 
axenic amastigotes and alamarBlue. The main SAR findings are described in 
Figure 26. Substitution in the right-hand side of the core structure was 
studied, and meta-substitution seems to be preferred. The linker part could 
be shortened and modified without losing activity. The benzoxadiazole ring is 
not essential for antileishmanial activity and could be replaced with other 
heterocycles. Even removal of the ring fails to abolish the antileishmanial 
activity completely. 
 
 
Figure 26 SAR of the benzoxadiazoles and related derivatives as antileishmanial compounds. 
Order of the substituent and structural parts in figure are based on L. donovani % 
inhibition values (axenic amastigotes). 
The best compounds in this study were carboxyimidamide-substituted 24 
and N,N’-oxydiamide 54 (Figure 27). They have low IC50 values on axenic 
amastigotes and no signs of cytotoxicity against fibroblasts (Table 7). Further 
modification of the structure, especially its linker part, could be planned to 
study SAR more thoroughly and hopefully to reach nanomolar 
antileishmanial activity. 
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Figure 27 The best L. donovani growth inhibiting compound (24, 54) in this study. 
Table 7. IC50 on axenic amastigotes, cytotoxicity on NIH/3T3 fibroblasts and selectivity 
 indices of the best derivatives. 
Compound 
Axenic amastigotes   
IC50 (µM) 
Fibroblasts IC50 
(µM) 
SI 
24 4.0 >300 >58 
54 5.2 >300 >75 
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5 SUMMARY AND CONCLUSIONS 
Resistance to antimicrobial agents is alarmingly increasing, and parasitic 
diseases still commonly threaten millions of people. This is why, every effort 
to support and facilitate studies of novel antimicrobial agents is beneficial. 
The heterocyclic structures, in turn, are the key fragments commonly used in 
drug design and found in the chemical structures of the approved drugs and 
active pharmaceutical ingredients. This thesis focuses on benzimidazoles and 
benzo[c][1,2,5]oxadiazoles. This study enhances knowledge of 2-
arylbenzimidazole, 2-aminobenzimidazole, and benzo[c][1,2,5]oxadiazole 
derivatives against intracellular pathogens, Chlamydia pneumoniae, 
Leishmania donovani, and Plasmodium falciparum, causative microbes of 
such diseases as lung chlamydia, leishmaniasis, and malaria. 
The initial finding of 2-arylbenzimidazoles as antichlamydial compounds 
was based on in silico screening, and the subsequent study of benzimidazoles 
as antimalarial compounds was initiated because of positive benzimidazole 
hit compounds found by the phenotypic HTS screening. Design of 2-
arylbenzimidazoles during antichlamydial and antileishmanial studies as well 
as 2-aminobenzimidazoles as antimalarial agents were based on the iterative 
SAR studies. Derivatives in all studies have been designed to cover enough 
structural variations in the compound series to find and identify potent 
antimicrobial compounds. We have shown that antimicrobial compound 
design can be performed successfully without unambiguous macromolecular 
targets. 
Various methods to synthesize the benzimidazole moiety were used, and 
in every case, the most practical methods were selected. Facile synthesis 
routes to prepare benzimidazole and benzo[c][1,2,5]oxadiazole derivatives 
were developed. 
2-Arylbenzimidazoles were studied as antichlamydial agents. meta-
Methyl derivative 33 inhibited C. pneumoniae CWL-029 (IC50 10 µM) 
without affecting host cell viability. In addition, antichlamydial effect was 
confirmed by using strain CV-6 (IC50 6.3 µM). A low minimum 
chlamydiocidal concentration of the derivative 33 indicates chlamydiocidal 
effect. In the antileishmanial study, the best 2-arylbenzimidazole 42 
inhibited L. donovani-infected THP-1 cells 46% at concentration of 5 µM. 
Overall, according to our study the 2-arylbenzimidazole scaffold cannot be 
regarded as firmly associated to cellular cytotoxicity and this is why, careful 
attention should be paid to structure-cytotoxicity analyses in further studies. 
Antichlamydial, antileishmanial, and antimalarial SAR of the 2-
arylbenzimidazoles differ considerably. The main findings are the following: 
tolerance for NH alkylation (L. donovani tolerated), differences in 
substitution of the right-hand side ring (para substitution not tolerated in 
antichlamydial compound), and differences of the linker (amide) position 
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(antichlamydial and antileishmanial compounds). 3,5-Disubstitution of the 
D-ring increased antimalarial activity. The benzimidazole phenyl ring was 
shown to be essential for antichlamydial, antileishmanial, and antimalarial 
activities of the assayed compounds. In antichlamydial compounds, the high 
inhibition activity was related to non-planar orientation between C- and D-
ring in the right-hand side of the molecule, and antileishmanial activity 
seems to be more related to the electronic nature of the substituents. 
In the study of 2-aminobenzimidazoles as antimalarial compounds, 
derivative 12 inhibited growth of P. falciparum 3D7A (IC50 94 nM), although 
its activity was reduced against resistant strains. Solubility, cytotoxicity, and 
pharmacokinetic parameters were promising for derivative 12, and it was 
forwarded to in vivo test to confirm in vivo efficacy of this structural group. 
Derivative 12 was efficacious upon once a day oral administration, and was 
able to reduce parasitemia under limit of detection with just two doses (100 
mg/kg), killing parasite rapidly. 
Furthermore, benzoxadiazole derivatives showed antileishmanial activity. 
The best compound was the 3-chloro derivative (24) of the carboxy-
imidamide substituted derivatives and N,N'-oxydiamide-benzoxadiazole 
derivative 54. They inhibit the growth of L. donovani having IC50 4.0 and 5.6 
µM, respectively without any sign of cytotoxicity against fibroblasts. 
Selectivity of the 2-arylbenzimidazoles over free living (planktonic) 
pathogens e.g. E. coli is an advantage. For example, during an oral 
administration regimen, it is a great advantage if normal microbial flora of 
the gut is not affected by the antimicrobial agent employed. The observed 
selectivity enhances possibilities of the successful development of these 
compounds further. Overall, it is known that benzimidazole derivatives have 
shown wide variety of biological activities. However, we have shown that the 
benzimidazole scaffold can be used due to its feasible chemical modification 
protocols as a versatile starting point to study antibacterial and antiparasitic 
compounds and their structure-activity relationships. 
Mechanisms of action of the derivatives remain elusive, and further 
studies should be conducted to clarify those. Our current level of knowledge 
is that benzimidazole derivatives can affect all three intracellular target 
pathogens studied (Chlamydia pneumoniae, Leishmania donovani, and 
Plasmodium falciparum), and possibly penetrate their cell membranes. The 
2-arylbenzdimidazole derivatives inhibit growth of C. pneumoniae and affect 
the amastigote form of L. donovani. The antimalarial 2-aminobenzimidazole 
derivatives clearly affect the blood stage of malaria. 
2-Arylbenzimidazoles as antichlamydial compounds still show very 
interesting aspects from the medicinal chemistry point of view, as very small 
modifications affect the antichlamydial inhibition activity. As antileishmanial 
compounds both 2-arylbenzimidazoles and benzoxadiazoles would need 
changes to their current chemical structures to reach nanomolar activities 
and unequivocal structure-activity relationships. Moreover, possible 
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cytotoxicity issues related to 2-arylbenzimidazoles need to be addressed since 
cytotoxicity varies considerably between different derivatives. 
The antimicrobial compound design without the knowledge on their 
macromolecular targets could be continued, but increase in potency should 
be achieved. In addition, most of our current heterocyclic derivatives are still 
relatively lipophilic, so further modifications of their chemical structures 
would be needed to overcome issues related to lipophilicity and its 
implications to other critical physicochemical and pharmacokinetic 
parameters. Nanomolar activity of the benzimidazole-derived compound was 
reached in the antimalarial study of this thesis. 2-Aminobenzimidazole 
derivatives could be studied further. Their properties for further 
development are the most promising of all the compounds assayed during 
this study. 
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